Germany · Delayed Price · Currency is EUR Akero Therapeutics Company Description
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States.
The company’s lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients.
It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases.
The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018.
Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2017 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 63 |
| CEO | Andrew Cheng |
Contact Details
Address: 601 Gateway Boulevard South San Francisco, Delaware 94080 United States | |
| Phone | 650 487 6488 |
| Website | akerotx.com |
Stock Details
| Ticker Symbol | 0K4 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Andrew Cheng | Chief Executive Officer |
| William White | Chief Financial Officer |
| Jonathan Young | Chief Operating Officer |